↓ Skip to main content

Dove Medical Press

Primary lung sarcoma treated with stereotactic ablative radiotherapy: a case report

Overview of attention for article published in OncoTargets and therapy, July 2017
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

twitter
3 X users
facebook
1 Facebook page

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
11 Mendeley
Title
Primary lung sarcoma treated with stereotactic ablative radiotherapy: a case report
Published in
OncoTargets and therapy, July 2017
DOI 10.2147/ott.s138595
Pubmed ID
Authors

Seung-Gu Yeo

Abstract

Primary lung sarcoma (PLS) is an extremely rare, very aggressive malignancy. Surgical removal is considered the treatment of choice, and patients who have been given conventional radiotherapy have had inferior outcomes. This study is the first describing a case of PLS treated with stereotactic ablative radiotherapy (SABR), which precisely targets a small tumor with a markedly higher biologically effective dose than conventional radiotherapy. The patient was an 82-year-old man who was diagnosed with primary lung leiomyosarcoma based on radiology, pathology, and immunohistochemical examinations. The PLS was located in the right lower lobe and measured 2.5 cm. No regional nodal or distant organ metastasis was observed. He was inoperable medically. The SABR was performed using volumetric modulated arc therapy and a dose of 56 Gy in four fractions. Follow-up computed tomography 2 months after SABR revealed a complete tumor response. The toxicity was limited to mild respiratory symptoms. The patient is alive and has had no evidence of disease for 2 years. This study suggests that SABR can be a safe and effective treatment option for PLS.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 11 100%

Demographic breakdown

Readers by professional status Count As %
Other 3 27%
Student > Ph. D. Student 1 9%
Unspecified 1 9%
Researcher 1 9%
Student > Bachelor 1 9%
Other 0 0%
Unknown 4 36%
Readers by discipline Count As %
Medicine and Dentistry 2 18%
Arts and Humanities 1 9%
Nursing and Health Professions 1 9%
Unspecified 1 9%
Unknown 6 55%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 July 2017.
All research outputs
#14,605,790
of 25,382,440 outputs
Outputs from OncoTargets and therapy
#722
of 3,016 outputs
Outputs of similar age
#160,578
of 326,871 outputs
Outputs of similar age from OncoTargets and therapy
#21
of 72 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 326,871 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 72 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.